{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:55:46Z","timestamp":1790286946435,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T00:00:00Z","timestamp":1729900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T00:00:00Z","timestamp":1729900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Hunan Provincial Key Laboratory of the Traditional Chinese Medicine Agricultural Biogenomics and"},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2023JJ30847"],"award-info":[{"award-number":["2023JJ30847"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-024-03484-1","type":"journal-article","created":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T15:01:59Z","timestamp":1729954919000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Clinical characteristics, treatment and outcome of subacute cutaneous lupus erythematosus induced by PD-1\/PD-L1 inhibitors"],"prefix":"10.1007","volume":"316","author":[{"given":"Zhaoquan","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binsheng","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunjiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,26]]},"reference":[{"key":"3484_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/82_2010_116","volume":"350","author":"HT Jin","year":"2011","unstructured":"Jin HT, Ahmed R, Okazaki T (2011) Role of PD-1 in regulating T-cell immunity. Curr Top Microbiol Immunol 350:17\u201337. https:\/\/doi.org\/10.1007\/82_2010_116","journal-title":"Curr Top Microbiol Immunol"},{"issue":"6382","key":"3484_CR2","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas A, Wolchok JD (2018) Cancer immunotherapy using checkpoint blockade. Science 359(6382):1350\u20131355. https:\/\/doi.org\/10.1126\/science.aar4060","journal-title":"Science"},{"issue":"5","key":"3484_CR3","doi-asserted-by":"publisher","first-page":"362","DOI":"10.3892\/mmr.2021.12001","volume":"23","author":"X Kong","year":"2021","unstructured":"Kong X, Lu P, Liu C, Guo Y, Yang Y, Peng Y, Wang F, Bo Z, Dou X, Shi H, Meng J (2021) A combination of PD-1\/PDL1 inhibitors: the prospect of overcoming the weakness of tumor immunotherapy (review). Mol Med Rep 23(5):362. https:\/\/doi.org\/10.3892\/mmr.2021.12001","journal-title":"Mol Med Rep"},{"issue":"1","key":"3484_CR4","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1517\/17425255.2016.1120287","volume":"12","author":"C Ciccarese","year":"2016","unstructured":"Ciccarese C, Alfieri S, Santoni M, Santini D, Brunelli M, Bergamini C et al (2016) New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors. Expert Opin Drug Metab Toxicol 12(1):57\u201375. https:\/\/doi.org\/10.1517\/17425255.2016.1120287","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"3484_CR5","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ctrv.2017.05.003","volume":"57","author":"JC Hassel","year":"2017","unstructured":"Hassel JC, Heinzerling L, Aberle J, B\u00e4hr O, Eigentler TK, Grimm MO et al (2017) Combined immune checkpoint blockade (anti-PD-1\/anti-CTLA-4): evaluation and management of adverse drug reactions. Cancer Treat Rev 57:36\u201349. https:\/\/doi.org\/10.1016\/j.ctrv.2017.05.003","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"3484_CR6","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.jaad.2015.10.029","volume":"74","author":"SJ Hwang","year":"2016","unstructured":"Hwang SJ, Carlos G, Wakade D, Byth K, Kong BY, Chou S et al (2016) Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort. J Am Acad Dermatol 74(3):455\u201361e. https:\/\/doi.org\/10.1016\/j.jaad.2015.10.029","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"3484_CR7","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/cup.12858","volume":"44","author":"JL Curry","year":"2017","unstructured":"Curry JL, Tetzlaff MT, Nagarajan P, Drucker C, Diab A, Hymes SR et al (2017) Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. J Cutan Pathol 44(2):158\u2013176. https:\/\/doi.org\/10.1111\/cup.12858","journal-title":"J Cutan Pathol"},{"issue":"10","key":"3484_CR8","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1001\/jamadermatol.2016.2226","volume":"152","author":"VJ Shi","year":"2016","unstructured":"Shi VJ, Rodic N, Gettinger S, Leventhal JS, Neckman JP, Girardi M et al (2016) Clinical and histologic features of Lichenoid Mucocutaneous eruptions due to Anti-programmed Cell Death 1 and anti-programmed cell death Ligand 1 immunotherapy. JAMA Dermatol 152(10):1128\u20131136. https:\/\/doi.org\/10.1001\/jamadermatol.2016.2226","journal-title":"JAMA Dermatol"},{"issue":"3","key":"3484_CR9","doi-asserted-by":"publisher","first-page":"e104","DOI":"10.1111\/jdv.14579","volume":"32","author":"S Le Naour","year":"2018","unstructured":"Le Naour S, Peuvrel L, Saint-Jean M, Dreno B, Quereux G (2018) Three new cases of bullous pemphigoid during anti-PD-1 antibody therapy. J Eur Acad Dermatol Venereol 32(3):e104\u2013e106. https:\/\/doi.org\/10.1111\/jdv.14579","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"3484_CR10","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1111\/bjd.15237","volume":"176","author":"A Zarbo","year":"2017","unstructured":"Zarbo A, Belum VR, Sibaud V, Oudard S, Postow MA, Hsieh JJ et al (2017) Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors. Br J Dermatol 176(6):1649\u20131652. https:\/\/doi.org\/10.1111\/bjd.15237","journal-title":"Br J Dermatol"},{"issue":"5","key":"3484_CR11","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1097\/BOR.0000000000000522","volume":"30","author":"Y He","year":"2018","unstructured":"He Y, Sawalha AH (2018) Drug-induced lupus erythematosus: an update on drugs and mechanisms. Curr Opin Rheumatol 30(5):490\u2013497. https:\/\/doi.org\/10.1097\/BOR.0000000000000522","journal-title":"Curr Opin Rheumatol"},{"issue":"3","key":"3484_CR12","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1111\/j.1365-2133.2010.10110.x9","volume":"164","author":"GC Lowe","year":"2011","unstructured":"Lowe GC, Henderson CL, Grau RH, Hansen CB, Sontheimer RD (2011) A systematic review of drug-induced subacute cutaneous lupus erythematosus. Br J Dermatol 164(3):465\u2013472. https:\/\/doi.org\/10.1111\/j.1365-2133.2010.10110.x9","journal-title":"Br J Dermatol"},{"issue":"3","key":"3484_CR13","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/j.jaad.2020.10.054","volume":"84","author":"AN Bui","year":"2021","unstructured":"Bui AN, Singer S, Hirner J, Cunningham-Bussel AC, Larocca C, Merola JF et al (2021) De novo cutaneous connective tissue disease temporally associated with immune checkpoint inhibitor therapy: a retrospective analysis. J Am Acad Dermatol 84(3):864\u2013869. https:\/\/doi.org\/10.1016\/j.jaad.2020.10.054","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"3484_CR14","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1111\/j.1365-2133.2011.10397.x","volume":"165","author":"AV Marzano","year":"2011","unstructured":"Marzano AV, Lazzari R, Polloni I, Crosti C, Fabbri P, Cugno M (2011) Drug-induced subacute cutaneous lupus erythematosus: evidence for differences from its idiopathic counterpart. Br J Dermatol 165(2):335\u2013341. https:\/\/doi.org\/10.1111\/j.1365-2133.2011.10397.x","journal-title":"Br J Dermatol"},{"issue":"2","key":"3484_CR15","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1046\/j.1440-0960.2001.00491.x","volume":"42","author":"C Ho","year":"2001","unstructured":"Ho C, Shumack SP, Morris D (2001) Subacute cutaneous lupus erythematosus associated with hepatocellular carcinoma. Australas J Dermatol 42(2):110\u2013113. https:\/\/doi.org\/10.1046\/j.1440-0960.2001.00491.x","journal-title":"Australas J Dermatol"},{"issue":"10","key":"3484_CR16","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","volume":"32","author":"SL Topalian","year":"2014","unstructured":"Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH et al (2014) Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32(10):1020\u20131030. https:\/\/doi.org\/10.1200\/JCO.2013.53.0105","journal-title":"J Clin Oncol"},{"issue":"11","key":"3484_CR17","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1177\/0961203309106176","volume":"18","author":"AV Marzano","year":"2009","unstructured":"Marzano AV, Vezzoli P, Crosti C (2009) Drug-induced lupus: an update on its dermatologic aspects. Lupus 18(11):935\u2013940. https:\/\/doi.org\/10.1177\/0961203309106176","journal-title":"Lupus"},{"issue":"3","key":"3484_CR18","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1001\/jamadermatol.2013.10393","volume":"150","author":"AB Eastham","year":"2014","unstructured":"Eastham AB, Vleugels RA (2014) Cutaneous lupus erythematosus. JAMA Dermatol 150(3):344. https:\/\/doi.org\/10.1001\/jamadermatol.2013.10393","journal-title":"JAMA Dermatol"},{"key":"3484_CR19","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2147\/CCID.S344445","volume":"13","author":"N Pratumchart","year":"2022","unstructured":"Pratumchart N, Chanprapaph K, Topibulpong N, Tankunakorn J (2022) Subacute Cutaneous Lupus Erythematosus-Like Eruption Induced by Durvalumab: a Case Report and Literature Review. Clin Cosmet Investig Dermatol 13:15:51\u201362. https:\/\/doi.org\/10.2147\/CCID.S344445","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"5","key":"3484_CR20","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1046\/j.1365-2133.2001.04182.x","volume":"144","author":"B Baima","year":"2001","unstructured":"Baima B, Sticherling M (2001) Apoptosis in different cutaneous manifestations of lupus erythematosus. Br J Dermatol 144(5):958\u2013966. https:\/\/doi.org\/10.1046\/j.1365-2133.2001.04182.x","journal-title":"Br J Dermatol"},{"issue":"3","key":"3484_CR21","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1111\/bjd.17245","volume":"181","author":"AL Marano","year":"2018","unstructured":"Marano AL, Clarke JM, Morse MA, Shah A, Barrow W, Selim MA et al (2018) Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy. Br J Dermatol 181(3):580\u2013583. https:\/\/doi.org\/10.1111\/bjd.17245","journal-title":"Br J Dermatol"},{"issue":"1\u20132","key":"3484_CR22","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s12016-007-0031-x12","volume":"33","author":"JH Lin","year":"2007","unstructured":"Lin JH, Dutz JP, Sontheimer RD, Werth VP (2007) Pathophysiology of cutaneous lupus erythematosus. Clin Rev Allergy Immunol 33(1\u20132):85\u2013106. https:\/\/doi.org\/10.1007\/s12016-007-0031-x12","journal-title":"Clin Rev Allergy Immunol"},{"issue":"10","key":"3484_CR23","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1001\/jamadermatol.2016.222613","volume":"152","author":"VJ Shi","year":"2016","unstructured":"Shi VJ, Rodic N, Gettinger S, Leventhal JS, Neckman JP, Girardi M et al (2016) Clinical and histologic features of lichenoid mucocutaneous eruptions due to anti-programmed cell death 1 and anti-programmed cell death ligand 1 immunotherapy. JAMA Dermatol 152(10):1128\u20131136. https:\/\/doi.org\/10.1001\/jamadermatol.2016.222613","journal-title":"JAMA Dermatol"},{"issue":"2","key":"3484_CR24","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/nri72414","volume":"2","author":"CL Vanderlugt","year":"2002","unstructured":"Vanderlugt CL, Miller SD (2002) Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol 2(2):85\u201395. https:\/\/doi.org\/10.1038\/nri72414","journal-title":"Nat Rev Immunol"},{"key":"3484_CR25","doi-asserted-by":"publisher","unstructured":"Chanprapaph K, Limtong P, Ngamjanyaporn P, Suchonwanit P (2021) Trichoscopic signs in dermatomyositis, systemic lupus erythematosus, and systemic sclerosis: a comparative study of 150 patients. Dermatology 1\u201311. https:\/\/doi.org\/10.1159\/00052029715","DOI":"10.1159\/00052029715"},{"issue":"4","key":"3484_CR26","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/j.jaad.2019.08.04518","volume":"82","author":"O HHasan Ali","year":"2020","unstructured":"HHasan Ali O, Bomze D, Ring SS, Berner F, F\u00e4ssler M, Diem S et al (2020) BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors. J Am Acad Dermatol 82(4):854\u2013861. https:\/\/doi.org\/10.1016\/j.jaad.2019.08.04518","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"3484_CR27","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1093\/annonc\/mdw64020","volume":"28","author":"JC Osorio","year":"2017","unstructured":"Osorio JC, Ni A, Chaft JE, Pollina R, Kasler MK, Stephens D et al (2017) Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Ann Oncol 28(3):583\u2013589. https:\/\/doi.org\/10.1093\/annonc\/mdw64020\"","journal-title":"Ann Oncol"},{"issue":"26","key":"3484_CR28","doi-asserted-by":"publisher","first-page":"10468","DOI":"10.1073\/pnas.1201131109","volume":"109","author":"J Gotot","year":"2012","unstructured":"Gotot J, Gottschalk C, Leopold S, Knolle PA, Yagita H, Kurts C et al (2012) Regulatory T cells use programmed death 1 ligands to directly suppress autoreactive B cells in vivo. Proc Natl Acad Sci U S A 109(26):10468\u201310473. https:\/\/doi.org\/10.1073\/pnas.1201131109","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"3484_CR29","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/art.11442","volume":"50","author":"L Prokunina","year":"2004","unstructured":"Prokunina L, Gunnarsson I, Sturfelt G, Truedsson L, Seligman VA, Olson JL et al (2004) The systemic lupus erythematosus-associated PDCD1 polymorphism PD1.3A in lupus nephritis. Arthritis Rheum 50(1):327\u2013328. https:\/\/doi.org\/10.1002\/art.11442","journal-title":"Arthritis Rheum"},{"issue":"10","key":"3484_CR30","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1080\/1744666X.2016.1188006","volume":"12","author":"J Chang","year":"2016","unstructured":"Chang J, Werth VP (2016) Therapeutic options for cutaneous lupus erythematosus: recent advances and future prospects. Expert Rev Clin Immunol 12(10):1109\u20131121. https:\/\/doi.org\/10.1080\/1744666X.2016.1188006","journal-title":"Expert Rev Clin Immunol"},{"issue":"5","key":"3484_CR31","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.jaad.2020.03.1324","volume":"83","author":"AN Geisler","year":"2020","unstructured":"Geisler AN, Phillips GS, Barrios DM, Wu J, Leung DYM, Moy AP et al (2020) Immune checkpoint inhibitor-related dermatologic adverse events. J Am Acad Dermatol 83(5):1255\u20131268. https:\/\/doi.org\/10.1016\/j.jaad.2020.03.1324","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"3484_CR32","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1111\/bjd.1531224","volume":"177","author":"F Chasset","year":"2017","unstructured":"Chasset F, Bouaziz JD, Costedoat-Chalumeau N, Franc\u00e8s C, Arnaud L (2017) Efficacy and comparison of antimalarials in cutaneous lupus erythematosus subtypes: a systematic review and meta-analysis. Br J Dermatol 177(1):188\u2013196. https:\/\/doi.org\/10.1111\/bjd.1531224","journal-title":"Br J Dermatol"},{"issue":"2","key":"3484_CR33","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1111\/ced.14449","volume":"46","author":"AN Bui","year":"2021","unstructured":"Bui AN, Hirner J, Singer SB, Eberly-Puleo A, Larocca C, Lian CG, LeBoeuf NR (2021) De novo subacute cutaneous lupus erythematosus-like eruptions in the setting of programmed death-1 or programmed death ligand-1 inhibitor therapy: clinicopathological correlation. Clin Exp Dermatol 46(2):328\u2013337. https:\/\/doi.org\/10.1111\/ced.14449","journal-title":"Clin Exp Dermatol"},{"issue":"7","key":"3484_CR34","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1136\/annrheumdis-2018-213677","volume":"78","author":"JM Michot","year":"2019","unstructured":"Michot JM, Fusellier M, Champiat S, Velter C, Baldini C, Voisin AL et al (2019) Drug-induced lupus erythematosus following immunotherapy with anti-programmed death-(ligand) 1. Ann Rheum Dis 78(7):e67. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213677","journal-title":"Ann Rheum Dis"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03484-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-024-03484-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03484-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T16:07:34Z","timestamp":1732205254000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-024-03484-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,26]]},"references-count":34,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3484"],"URL":"https:\/\/doi.org\/10.1007\/s00403-024-03484-1","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,26]]},"assertion":[{"value":"8 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"722"}}